Want to see DE:ILM1 full AI Analyst Report?
Top Page
Medios AG
(XETRA:ILM1)
Select Model
Select Model
Rating:55Neutral
Price Target:
€11.50
▲(5.50% Upside)
Action:Reiterated
Date:08/19/26
Overall score reflects mixed fundamentals with strong revenue growth but very thin profitability and weakening free cash flow, combined with clearly bearish technicals (price below all key moving averages and negative MACD). Valuation is neutral (P/E ~19.9) with no dividend yield data to provide additional support.
Positive Factors
Strong Revenue Growth
The exceptional top-line expansion indicates strong demand for specialty-pharmaceutical distribution and patient-specific therapy services. Sustained growth can improve scale, deepen pharmacy relationships, and create operating leverage if profitability improves.
Negative Factors
Very Thin Profitability
Thin margins leave limited protection against supplier costs, pricing pressure, operating expenses, or unfavorable product mix. Even substantial revenue growth may therefore produce only modest earnings, constraining reinvestment and increasing earnings sensitivity.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
The exceptional top-line expansion indicates strong demand for specialty-pharmaceutical distribution and patient-specific therapy services. Sustained growth can improve scale, deepen pharmacy relationships, and create operating leverage if profitability improves.
Read all positive factors
Medios AG (ILM1) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€278.01M
Dividend YieldN/A
Average Volume (3M)45.28K
Price to Earnings (P/E)25.3
Beta (1Y)1.02
Revenue Growth9.88%
EPS Growth-38.44%
CountryDE
Employees989
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.44
Shares Outstanding25,505,724
10 Day Avg. Volume55,289
30 Day Avg. Volume45,276
Financial Highlights & Ratios
PEG Ratio1.21
Price to Book (P/B)0.71
Price to Sales (P/S)0.17
P/FCF Ratio9.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.00Price Target Upside92.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.3
Revenue Forecast (FY)€2.12B
Medios AG Business Overview & Revenue Model
Company Description
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therap...
How the Company Makes Money
Medios AG generates revenue primarily from the sale and distribution of specialty pharmaceuticals and related services to healthcare customers, particularly pharmacies that require access to high-cost, specialized, or hard-to-source medicines. A k...
Medios AG Earnings Call Summary
Earnings Call Date:Nov 12, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment with strong financial performance and strategic advancements, despite some challenges in specific segments and increased costs related to acquisitions.Positive Updates
Record Q3 Performance
The company posted its best quarter ever with significant earnings growth. EBITDA pre margin reached 5% for the first time, driven by PST and Ceban.
Negative Updates
PST Segment Challenges
PST gross profit decreased due to deconsolidation of Kölsche Blister, regulatory headwinds, and increased performance-based payments.
Read all updates
Q3-2024 Updates
Positive
Negative
Record Q3 Performance
The company posted its best quarter ever with significant earnings growth. EBITDA pre margin reached 5% for the first time, driven by PST and Ceban.
Read all positive updates
Company Guidance
During the Q3 2024 earnings call for Medios AG, the company provided several key financial metrics and guidance highlights. The company achieved a revenue growth of more than 4% to EUR 1.4 billion for the first nine months of 2024, with a significant EBITDA pre increase of over 20% to EUR 55.8 million. The EBITDA pre margin reached the 5% mark for the first time, driven by strong performances in the PST and Ceban segments. Operational cash flow more than doubled to EUR 27.6 million, and the company confirmed its guidance for 2024, anticipating full-year revenues between EUR 1.9 billion and EUR 2.1 billion and an EBITDA pre in the range of EUR 82 million to EUR 91 million. The company also noted inorganic growth due to the acquisition of Ceban, contributing EUR 47.3 million in revenue and EUR 9.8 million in EBITDA pre for the period June through October 2024. Additionally, Medios is focusing on strategic priorities, including expanding operations into other European countries and entering the production of advanced therapies, with a commitment to maintaining high-quality personalized medicines.Medios AG Financial Statement Overview
Summary
Income Statement
61
Positive
Balance Sheet
67
Positive
Cash Flow
54
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.16B | 2.08B | 1.88B | 1.78B | 1.61B | 1.36B |
| Gross Profit | 115.92M | 91.93M | 151.46M | 108.63M | 106.87M | 68.48M |
| EBITDA | 80.64M | 79.59M | 64.00M | 52.82M | 51.33M | 34.68M |
| Net Income | 11.19M | 15.37M | 12.55M | 18.81M | 18.33M | 7.40M |
Balance Sheet | ||||||
| Total Assets | 919.03M | 903.04M | 934.36M | 594.75M | 575.96M | 524.14M |
| Cash, Cash Equivalents and Short-Term Investments | 83.16M | 81.84M | 106.00M | 71.04M | 79.21M | 168.43M |
| Total Debt | 200.02M | 188.89M | 238.37M | 17.15M | 17.63M | 49.71M |
| Total Liabilities | 395.48M | 388.82M | 424.17M | 125.95M | 127.91M | 129.98M |
| Stockholders Equity | 523.55M | 514.22M | 510.19M | 468.81M | 448.05M | 394.16M |
Cash Flow | ||||||
| Free Cash Flow | 23.94M | 36.94M | 67.36M | 15.14M | 32.06M | 48.70M |
| Operating Cash Flow | 34.98M | 43.00M | 73.67M | 16.41M | 37.12M | 61.52M |
| Investing Cash Flow | -9.91M | -4.78M | -222.28M | -16.57M | -86.54M | 17.36M |
| Financing Cash Flow | -29.72M | -62.60M | 183.80M | -8.01M | -39.80M | 69.76M |
Medios AG Technical Analysis
Neutral
10.90
Price Trends
11.74
Negative
12.44
Negative
13.65
Negative
Market Momentum
-0.24
Negative
45.69
Neutral
40.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:ILM1, the sentiment is Neutral. The current price of 10.9 is below the 20-day moving average (MA) of 11.05, below the 50-day MA of 11.74, and below the 200-day MA of 13.65, indicating a neutral trend. The MACD of -0.24 indicates Negative momentum. The RSI at 45.69 is Neutral, neither overbought nor oversold. The STOCH value of 40.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:ILM1.
Medios AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | €322.95M | 15.53 | 18.60% | 6.83% | 7.40% | 38.17% | |
72 Outperform | €172.50M | 29.29 | 24.05% | 1.79% | 33.49% | 81.79% | |
55 Neutral | €278.01M | 25.32 | 2.16% | ― | 9.88% | -38.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | €19.29M | -1.22 | 21.40% | ― | 3.53% | -5.29% |
* Healthcare Sector Average
DE:ILM1
Medios AG
11.14
-3.68
-24.83%
DE:MAK
MATERNUS-Kliniken AG
0.92
-0.26
-22.03%
DE:LIK
Limes Schlosskliniken AG
565.00
237.36
72.45%
DE:EIF
Eifelhoehen-Klinik AG
3.96
2.03
105.18%
DE:JTH0
Gesundheitswelt Chiemgau AG
10.60
-1.40
-11.67%
DE:M12
M1 Kliniken AG
18.64
6.19
49.68%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.